Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sales Force Downsizing By Big Pharma Means Small/Mid-Tier Boom, CSOs Say

Executive Summary

Sales force restructuring among large pharmaceutical companies is helping to drive contract sales agreements with small and mid-tier companies, contract sales organizations say

You may also be interested in...

Waiting For Pfizer: GSK Will Cut Sales Force Should Pfizer Act First

GlaxoSmithKline will reduce the size of its sales force and reinvest those expenditures in research and development should Pfizer decide to downsize its sales team, GSK CEO J.P. Garnier said

Industry Cost Structure Must Change, But Will Not Start At AstraZeneca – CEO

AstraZeneca CEO Tom McKillop called on the pharmaceutical industry to reduce the costs associated with selling and marketing drugs, but does not believe his company will be the catalyst for change

AstraZeneca Cuts Sales Reps By Reducing PDI Contract; Will Others Follow?

AstraZeneca's decision to reduce the number of contract sales reps may be an early indicator of an industry trend in 2005

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts